Recommended Next Antihypertensive After Discontinuing Telmisartan/Amlodipine Due to Constipation
Add a thiazide diuretic (chlorthalidone 12.5–25 mg daily or hydrochlorothiazide 25–50 mg daily) to your current regimen, as thiazides provide effective blood pressure control and do not cause constipation. 1
Understanding the Clinical Context
Your patient is experiencing constipation, which is not a typical side effect of either telmisartan (ARB) or amlodipine (dihydropyridine calcium channel blocker). 2 However, if you must change therapy:
First-Line Recommendation: Add Thiazide Diuretic
Thiazide diuretics are recommended as first-line antihypertensive agents and work synergistically with most other drug classes, particularly when blood pressure remains uncontrolled. 1
Chlorthalidone (12.5–25 mg once daily) is preferred over hydrochlorothiazide due to its longer half-life and superior cardiovascular outcomes in clinical trials. 3
Thiazides do not cause constipation and are particularly effective in elderly patients and those with isolated systolic hypertension. 1
Monitor electrolytes (potassium, sodium), renal function, uric acid, and calcium levels within 2–4 weeks after initiating thiazide therapy. 3
Alternative Strategy: Switch to ACE Inhibitor + Thiazide
If you prefer to replace the ARB entirely:
Substitute telmisartan with an ACE inhibitor (lisinopril 10–40 mg daily, enalapril 5–40 mg daily, or ramipril 2.5–20 mg daily) combined with a thiazide diuretic. 1, 3
ACE inhibitors have compelling indications for patients with diabetes, chronic kidney disease, heart failure, or post-myocardial infarction. 1
Common side effect: dry cough occurs in 5–20% of patients on ACE inhibitors; if this develops, return to an ARB. 1
Monitor serum potassium and creatinine within 1–2 weeks after starting an ACE inhibitor, as hyperkalemia and azotemia are potential complications. 3
If Beta-Blocker is Needed
Add a beta-blocker (metoprolol, carvedilol, or bisoprolol) if the patient has compelling indications such as coronary artery disease, heart failure, or post-myocardial infarction. 1
Beta-blockers are not first-line for uncomplicated hypertension but are highly effective when combined with other agents. 1
Do NOT combine beta-blockers with non-dihydropyridine calcium channel blockers (diltiazem or verapamil) due to increased risk of bradycardia and heart block. 1, 3
Adding Mineralocorticoid Receptor Antagonist for Resistant Hypertension
If blood pressure remains uncontrolled on 3+ medications:
Spironolactone (12.5–50 mg daily) provides significant additional blood pressure reduction (average 25/12 mmHg) when added to existing multidrug regimens including diuretics and ACE inhibitors/ARBs. 1
Monitor serum potassium and creatinine closely when combining spironolactone with ACE inhibitors or ARBs, as hyperkalemia risk is substantial. 1
The combination of ACE inhibitor + ARB + mineralocorticoid antagonist is contraindicated due to excessive risk of renal dysfunction and hyperkalemia. 1
Critical Medications to Avoid
Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) should be avoided as they commonly cause constipation and have negative inotropic effects. 1
Alpha-blockers (doxazosin) should be avoided as first-line therapy due to increased heart failure risk demonstrated in the ALLHAT trial. 1
NSAIDs should be discontinued or minimized as they interfere with blood pressure control, cause sodium/water retention, and worsen renal function. 1
Loop diuretics are not appropriate for routine hypertension management unless the patient has heart failure or significant renal impairment (CrCl <30 mL/min). 1
Monitoring After Therapy Change
Recheck blood pressure within 2–4 weeks to ensure adequate control (target <130/80 mmHg for most patients). 3
Obtain basic metabolic panel to monitor electrolytes and renal function, particularly if adding thiazides or ACE inhibitors/ARBs. 3
Assess for new symptoms including dizziness, fatigue, or muscle cramps that may indicate electrolyte disturbances. 1